WKL Stock Analysis: Wolters Kluwer | AS

Specialty Business Services | AS, Netherlands | Market Cap: 13.373m EUR | 12M Return: -53.7% | Charts, Fundamentals & Technical Analysis

Clinical Software, Tax Software, Compliance Tools, Legal Analytics
Total Rating 39
Safety 53
Buy Signal 0.15
Specialty Business Services
Industry Rotation: -3.1
Market Cap: 15.2B
Avg Turnover: 66.7M
Risk 3d forecast
Volatility31.3%
VaR 5th Pctl5.20%
VaR vs Median1.07%
Reward TTM
Sharpe Ratio-2.07
Rel. Str. IBD5.1
Rel. Str. Peer Group6.3
Character TTM
Beta0.107
Beta Downside0.374
Hurst Exponent0.569
Drawdowns 3y
Max DD67.85%
CAGR/Max DD-0.23
CAGR/Mean DD-0.77
EPS (Earnings per Share) EPS (Earnings per Share) of WKL over the last years for every Quarter: "2021-06": 1.37, "2021-09": 0, "2021-12": 2.78, "2022-03": 0, "2022-06": 1.76, "2022-09": 0, "2022-12": 4.01, "2023-03": 0, "2023-06": 2.35, "2023-09": 0, "2023-12": 2.38, "2024-03": 0, "2024-06": 2.36, "2024-09": 0, "2024-12": 2.61, "2025-03": 0, "2025-06": 2.7, "2025-09": 0, "2025-12": 3.2768,
EPS CAGR: -2.90%
EPS Trend: -22.9%
Qual. Beats: 0
Revenue Revenue of WKL over the last years for every Quarter: 2021-06: 2280, 2021-09: 1192.75, 2021-12: 2491, 2022-03: null, 2022-06: 2600, 2022-09: null, 2022-12: 2853, 2023-03: null, 2023-06: 2725, 2023-09: null, 2023-12: 2859, 2024-03: null, 2024-06: 2891, 2024-09: null, 2024-12: 3025, 2025-03: null, 2025-06: 3052, 2025-09: null, 2025-12: 3073,
Rev. CAGR: 4.38%
Rev. Trend: 98.0%
Last SUE: -0.02
Qual. Beats: 0

Warnings

Altman Z'' In Financial Distress Zone
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 10.5 years of data

Jan +1.1% 26
Feb -2.7% 15
Mar +0.7% 2
Apr +1.7% 25
May +0.5% 0
Jun -1.1% 25
Jul -0.5% 8
Aug -2.9% 41
Sep +0.3% 8
Oct -2.5% 6
Nov +0.6% 19
Dec -1.4% 33

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: WKL Wolters Kluwer

Wolters Kluwer N.V. (WKL) is a Netherlands-headquartered information services company founded in 1836, based in Alphen aan den Rijn. It provides professional information, software, and services through five operating segments: Health; Tax & Accounting; Financial & Corporate Compliance; Legal & Regulatory; and Corporate Performance & ESG. Its products target specialized professional end markets, including hospitals and clinicians, tax and accounting firms, financial institutions, law firms, corporate legal departments, and government entities, with operations spanning Europe, North America, and Asia Pacific.

The company operates as a B2B professional information and software provider, selling subscription-based content, compliance tools, and workflow software to expert users in regulated industries. It is classified in the GICS Industrials sector under Diversified Support Services, reflecting its mix of data, analytics, and software products rather than a pure media or pure software profile.

Headlines to Watch Out For
  • GenAI-powered Health solutions accelerate recurring subscription revenue growth
  • Regulatory complexity drives demand across Tax and Compliance software segments
  • Share buybacks offset EUR strength and subscription margin pressure
Piotroski VR-10 (Strict) 7.5
Net Income: 1.31b TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA -2.95 > 1.0
NWC/Revenue: -23.27% < 20% (prev -19.05%; Δ -4.22% < -1%)
CFO/TA 0.17 > 3% & CFO 1.67b > Net Income 1.31b
Net Debt (4.42b) to EBITDA (1.99b): 2.22 < 3
Current Ratio: 0.65 > 1.5 & < 3
Outstanding Shares: last quarter (230.4m) vs 12m ago -5.74% < -2%
Gross Margin: 69.49% > 18% (prev 68.26%; Δ 1.23% > 0.5%)
Asset Turnover: 64.20% > 50% (prev 62.29%; Δ 1.91% > 0%)
Interest Coverage Ratio: 17.16 > 6 (EBIT TTM 1.51b / Interest Expense TTM 88.0m)
Altman Z'' 0.58
A: -0.15 (Total Current Assets 2.63b - Total Current Liabilities 4.06b) / Total Assets 9.58b
B: 0.12 (Retained Earnings 1.17b / Total Assets 9.58b)
C: 0.16 (EBIT TTM 1.51b / Avg Total Assets 9.54b)
D: 0.09 (Book Value of Equity 798.0m / Total Liabilities 8.79b)
Altman-Z'' = 0.58 = B
Beneish M -2.99
DSRI: 1.03 (Receivables 1.64b/1.54b, Revenue 6.12b/5.92b)
GMI: 0.98 (GM 68.26% / 69.49%)
AQI: 1.01 (AQ_t 0.70 / AQ_t-1 0.69)
SGI: 1.04 (Revenue 6.12b / 5.92b)
TATA: -0.04 (NI 1.31b - CFO 1.67b) / TA 9.58b)
Beneish M = -2.99 (Cap -4..+1) = A
What is the price of WKL shares?

As of July 14, 2026, the stock is trading at EUR 62.44 with a total of 1,011,208 shares traded. Over the past week, the price has changed by +7.88%, over one month by +3.65%, over three months by +0.83% and over the past year by -53.69%.

Current recommended Stop Loss: 57.40 (which is 8.1% or 2.4 ATR below the current price).

Is WKL a buy, sell or hold?

Wolters Kluwer has no consensus analysts rating.

Wolters Kluwer (WKL) - Fundamental Data Overview as of 11 July 2026
Market Cap USD = 15.2b (13.4b EUR * 1.14 EUR.USD)
P/E Trailing = 10.6241
P/E Forward = 10.352
P/S = 2.1833
P/B = 16.5141
P/EG = 1.6974
Revenue TTM = 6.12b EUR
EBIT TTM = 1.51b EUR
EBITDA TTM = 1.99b EUR
Long Term Debt = 3.95b EUR (from longTermDebt, last quarter)
Short Term Debt = 778.0m EUR (from shortTermDebt, last quarter)
Debt = 5.35b EUR (from shortLongTermDebtTotal, last quarter) + Leases 217.0m
Net Debt = 4.42b EUR (calculated: Debt 5.35b - CCE 932.0m)
Enterprise Value = 17.8b EUR (13.4b + Debt 5.35b - CCE 932.0m)
Interest Coverage Ratio = 17.16 (Ebit TTM 1.51b / Interest Expense TTM 88.0m)
EV/FCF = 13.02x (Enterprise Value 17.8b / FCF TTM 1.37b)
FCF Yield = 7.68% (FCF TTM 1.37b / Enterprise Value 17.8b)
FCF Margin = 22.30% (FCF TTM 1.37b / Revenue TTM 6.12b)
Net Margin = 21.36% (Net Income TTM 1.31b / Revenue TTM 6.12b)
Gross Margin = 69.49% ((Revenue TTM 6.12b - Cost of Revenue TTM 1.87b) / Revenue TTM)
Gross Margin QoQ = 73.74% (prev 65.20%)
Tobins Q-Ratio = 1.86 (Enterprise Value 17.8b / Total Assets 9.58b)
Interest Expense / Debt = 1.65% (Interest Expense 88.0m / Debt 5.35b)
Taxrate = 20.68% (341.0m / 1.65b)
NOPAT = 1.20b (EBIT 1.51b * (1 - 20.68%))
Current Ratio = 0.65 (Total Current Assets 2.63b / Total Current Liabilities 4.06b)
Debt / Equity = 6.70 (Debt 5.35b / totalStockholderEquity, last quarter 798.0m)
Debt / EBITDA = 2.22 (Net Debt 4.42b / EBITDA 1.99b)
Debt / FCF = 3.23 (Net Debt 4.42b / FCF TTM 1.37b)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.71% (Net Income 1.31b / Total Assets 9.58b)
RoE = 109.7% (Net Income TTM 1.31b / Total Stockholder Equity 1.19b)
RoCE = 29.39% (EBIT 1.51b / Capital Employed (Equity 1.19b + L.T.Debt 3.95b))
RoIC = 19.97% (NOPAT 1.20b / Invested Capital 6.00b)
WACC = 4.92% (E(13.4b)/V(18.7b) * Re(6.36%) + D(5.35b)/V(18.7b) * Rd(1.65%) * (1-Tc(0.21)))
Discount Rate = 6.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -5.52%
[DCF] Terminal Value 73.10% ; FCFF base≈1.47b ; Y1≈1.29b ; Y5≈1.04b
[DCF] Fair Price = 55.29 (EV 16.8b - Net Debt 4.42b = Equity 12.3b / Shares 223.2m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -22.92 | EPS CAGR: -2.90% | SUE: N/A | # QB: 0
Revenue Correlation: 97.98 | Revenue CAGR: 4.38% | SUE: -0.02 | # QB: 0
EPS current Year (2026-12-31): EPS=5.62 | Chg30d=-0.05% | Revisions=+40% | GrowthEPS=+6.3% | GrowthRev=+2.4%
EPS next Year (2027-12-31): EPS=6.21 | Chg30d=+0.03% | Revisions=+25% | GrowthEPS=+10.5% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: +50% (up=3, down=0)